Technical reports
The Oslo Medicines Initiative (OMI) has commissioned a series of technical reports to review and analyze the relevant evidence and provide policy considerations as a basis for discussion to inform its work. Reports have been independently authored and externally peer reviewed by experts in the field.
These focus on the following topics:
- Overview of the market for novel medicines in the WHO European Region
- Towards a new vision for shared responsibility in pharmaceutical pricing, coverage and reimbursement: Policy approaches building on principles of solidarity, transparency and sustainability
- New business models for pharmaceutical research and development as a global public good: considerations for the WHO European Region
- Payer policies to support innovation and access to medicines in the WHO European Region
- Policy instruments (non-price) for medical innovation
- Access to information in markets for medicines in the WHO European Region
- Access to high-priced medicines in lower-income countries in the WHO European Region
- The social contract and human rights bases for promoting access to effective, novel, high-priced medicines.
Reports
Lower-income countries (LICs) in the WHO European Region generally have poorer health status and more limited resources than higher-income countries....
New business models for pharmaceutical research and development as a global public good: considerations...
Public concern has been increasing about the high prices of novel medicines, limits on availability and access, and the strain on health-care budgets across...
Towards a new vision for shared responsibility in pharmaceutical pricing, coverage and reimbursement:...
Concerns about affordable access to medicines reflect the emergence of new, high-priced medicines, as well as expectations regarding the cost of precision...
The Oslo Medicines Initiative (OMI) is a platform through which stakeholders can collaborate to develop ways of achieving better, more affordable...
Payer policies to support innovation and access to medicines in the WHO European Region
This Oslo Medicines Initiative technical report presents existing policy options for payers that support innovation and access to medicines in the WHO...
The social contract and human rights bases for promoting access to effective, novel, high-priced medicines
High prices can significantly restrict access to medicines and may have an impact on health equity. There is no clear understanding of what the social...
Access to information in markets for medicines in the WHO European Region. Oslo Medicines Initiative...
Transparency is important for good governance and evidence-informed policy-making for access to medicines. Based on a document review and validation...
Innovation policy instruments are policy interventions with a specific mechanism of action that influences the innovation process. This Oslo Medicines...
Oslo Medicines Initiative policy brief
Established in 2020, the Oslo Medicines Initiative (OMI) is a collaboration between the WHO Regional Office for Europe, the Norwegian Ministry...
Final report of the Oslo Medicines Initiative. Improving access to novel, high-priced medicines in the...
The market for pharmaceutical products has changed considerably in recent years, from a blockbuster model that targeted high volumes of patients,...